Cartesian Therapeutics, Inc. RNAC 深 沪
交易中 08-19 10:30:16 美东时间
9.51
+0.310
+3.37%
华盛通- 最 高9.9305
- 今 开9.50
- 成交量 3.82万股
- 最 低 9.3265
- 昨 收 9.20
- 总市值 2.88亿
- 52周最高 11.00
- 市盈率 静 --
- 换手率 0.13%
- 52周最低 5.60
- 委 比 -79.75%
- 总股本 3025.54万
- 历史最高 840.00
- 量 比 3.63
- 振 幅 6.57%
- 历史最低 5.60
- 每 手 1
- 风险率 1.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
今天 08:37
Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target
Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.
08-18 20:34
Cartesian Therapeutics Q2 EPS $0.46 Beats $(0.86) Estimate
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $(0.86) by 153.49 percent. This is a 8 percent decrease over earnings of $0.50 per share from the same period last year.
08-06 19:26
美股牛股 | NUVL飙升39%，获葛兰素史克高额溢价收购；Velo3D大涨近20%
NUVL飙升39%，获葛兰素史克高额溢价收购；Velo3D大涨近20%，进军燃气轮机增材制造领域；职业教育涨逾18%，收购整合完成后大幅上调营收预期>>
06-10 18:45
美股大行评级 | 潜在涨幅321.55%！Shattuck Labs获花旗升目标价至18美元，维持"买入"评级
今日重点评级关注：花旗：维持Shattuck Labs"买入"评级，目标价从7美元升至18美元；Benchmark：维持Gloo Holdings"买入"评级，目标价从14美元升至15美元
06-10 12:32
Cartesian Therapeutics Inks Licensing Agreement With Westgene Biopharma For In Vivo Chimeric Antigen Receptor T-cell Therapies In Autoimmune Diseases, For Undisclosed Upfront And Milestone Payments
WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translationPlans to advance multiple
06-09 19:11
美股大行评级 | 市值直指1.8万亿美元？瑞银给出美光1600美元天价目标！华尔街绩前集体上调迈威尔科技目标价
今日重点评级关注：Canaccord Genuity：维持Dakota Gold"投机性买入"评级，目标价从16美元升至18美元；瑞杰金融：上调Tectonic Therapeutic评级至"强烈买入"，目标价从76美元升至81美元
05-27 17:33
Cartesian Therapeutics Announces Non-Dilutive Financing Of Up To $150M From K2 HealthVentures; Expects Topline Data From Phase 3 AURORA Trial In Q1 2027
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that it has entered into an agreement with K2
05-26 19:05
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $25
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $30 to $25.
05-12 18:32
